PharmAla Announces Private Placement
13. Dezember 2024 09:25 ET
|
PharmAla Biotech
PharmAla announces private placement financing
PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License
14. November 2024 09:20 ET
|
PharmAla Biotech
PharmAla reaches agreement in principle to trade with a clinical trial to trade its LaNeo MDMA for a data license to the trial outcomes.
PharmAla to supply LaNeo MDMA for Clinical Trial at Yale
07. November 2024 09:20 ET
|
PharmAla Biotech
PharmAla to supply Yale University with MDMA for clinical trial
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
21. Oktober 2024 09:25 ET
|
PharmAla Biotech
PharmAla contracted to sell MDMA to Mt. Sinai Hospital, NY. Terminates Contract with CCrest Labs.
PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA
08. Oktober 2024 08:55 ET
|
PharmAla Biotech
PharmAla signs contract to develop novel dosage form of LaNeo MDMA, to be used in clinical trial at University of Texas San Antonio
PharmAla to supply Harvard Medical School’s Maclean Hospital with LaNeo MDMA
02. Oktober 2024 09:20 ET
|
PharmAla Biotech
PharmAla Biotech signs contract to supply Harvard neuropsychiatry hospital with MDMA; Appears at CPHI Conference in Milan
PharmAla to supply Johns Hopkins Medicine for Clinical Trial
11. September 2024 08:55 ET
|
PharmAla Biotech
PharmAla completes sales agreement with Johns Hopkins Medicine, terminates contract with Red Light Holland, to present novel molecule at conference.
PharmAla Launches MDMA Clinical Trial Tool for Researchers
22. August 2024 09:07 ET
|
PharmAla Biotech
PharmAla announces the launching of a new tool for clinical researchers, and the appointment of a new CFO effective Oct. 1
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
09. August 2024 18:18 ET
|
PharmAla Biotech
PharmAla expresses disappointment in USFDA's decision to request a third Phase 3 for MDMA and announces the patent granting for a safer MDMA analog variant
PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement
30. Juli 2024 08:55 ET
|
PharmAla Biotech
PharmAla releases a comprehensive investor update following its Q3 financial release, including highlights such as a 10x revenue increase and patent update